@socalplasticsurgeon shares five benefits they attribute to semaglutide and tirzepatide beyond weight loss. No sources or study details are given.
Recap by typeshit. Video by @socalplasticsurgeon on TikTok.
Experts say holding on to weight loss after quitting a GLP-1 is possible and walk through the habits they recommend for the transition.
The study of over 87,000 matched patients 65 and up also found 28% fewer liver decompensation events, but no drop in heart attack or stroke and more osteoporosis diagnoses.
18:05
Dr. Stirrett walks through three pointers for people on tirzepatide, framed as part of a broader GLP-1 guide. His advice, not a set protocol.
He walks through an Azoury et al study in the October 2026 Plastic and Reconstructive Surgery that uses global health network data to compare the two weight loss routes.
The same roundup notes Novo Nordisk plans to stop selling Saxenda in early 2027, and Zealand's petrelintide posted up to 9.2% weight loss in phase II.
Retatrutide is still in clinical trials, yet Eli Lilly is already up against a web of black market sellers offering it online.
Loading…